Comparison of the effect of ranibizumab and dexamethasone implant in diabetic macular edema with concurrent epiretinal membrane

Basit Öğe Kaydı
dc.authorid0000-0002-0972-3833
dc.contributor.authorÇakır, Akın
dc.contributor.authorErden, Burak
dc.contributor.authorAydın, Ali
dc.contributor.authorBölükbaşı, Selim
dc.contributor.authorAydın, Ali
dc.contributor.authorYurttasever Ocak, Serap
dc.contributor.authorMaden, Gamze
dc.contributor.authorElçioğlu, Mustafa Nuri
dc.date.accessioned2019-12-27T13:55:23Z
dc.date.available2019-12-27T13:55:23Z
dc.date.issued2019
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Göz Hastalıkları Ana Bilim Dalı
dc.description.abstractObjective. - To compare the efficacy and safety of intravitreal ranibizumab (RZB) injections and intravitreal dexamethasone (DEX) implant in diabetic macular edema (DME) with concurrent epiretinal membrane (ERM). Methods. - This was a retrospective, observational, comparative study. Medical records of DME patients with concurrent ERM were retrospectively reviewed. Seventeen eyes of 16 patients treated with 3 consecutive monthly RZB injections (RZB group) and 22 eyes of 18 patients treated with a DEX implant (DEX group) were included. The groups were compared at baseline, 1st, 2nd, 3rd and 4th months in terms of best-corrected visual acuity (BCVA), central macular thickness (CMT), and intraocular pressure (IOP). Results. - Eighteen of the 39 eyes (46.1%) were phakic at baseline, 9 (52.9%) of which were treated with RZB, whereas 9 (40.9%) were treated with DEX implant (P = 0.528). Although CMT improved significantly in both the RZB and DEX groups (P<0.001); the trend was different (P=0.003). The mean change in CMT at 1 month in the DEX group was greater (DEX: 188.2 +/- 142.7 mu m; RZB: 95.7 +/- 110.7 mu m; P=0.034); it was in favor of RZB group at the 3rd and 4th months (DEX: -52.7 +/- 86.9 mu m; RZB: 1.4 +/- 31.4 mu m; P=0.012. DEX: -63 +/- 67.3 mu m; RZB: -5.8 +/- 43.9 mu m; P=0.004, respectively). BCVA improved significantly in both groups (P < 0.001). There was no statistical difference between the groups with regard to gain in BCVA or IOP change throughout the study period (P=0.572, P=0.064, respectively). Conclusion. - Both RZB and DEX are effective in improving anatomical and visual outcomes in DME with concurrent ERM. The DEX group was associated with a prompt anatomic response, but with a gradual decrease from 3rd month.
dc.identifier.citationÇakır, A., Erden, B., Bölükbaşı, S., Aydın, A., Yurttasever Ocak, S., Maden, G. ... Elçioğlu, M. N. (2019). Comparison of the effect of ranibizumab and dexamethasone implant in diabetic macular edema with concurrent epiretinal membrane. Journal Francais D Ophtalmologie, 42(7), 683-689. https://doi.org/10.1016/j.jfo.2019.02.007
dc.identifier.doi10.1016/j.jfo.2019.02.007
dc.identifier.endpage689
dc.identifier.issn0181-5512
dc.identifier.issn1773-0597
dc.identifier.issue7
dc.identifier.scopusqualityQ3
dc.identifier.startpage683
dc.identifier.urihttps://doi.org/10.1016/j.jfo.2019.02.007
dc.identifier.urihttps://hdl.handle.net/20.500.12511/4779
dc.identifier.volume42
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherMasson Editeur
dc.relation.ispartofJournal Francais D Ophtalmologieen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectRanibizumab
dc.subjectDexamethasone
dc.subjectEpiretinal Membrane
dc.subjectDiabetic Macular Edema
dc.titleComparison of the effect of ranibizumab and dexamethasone implant in diabetic macular edema with concurrent epiretinal membrane
dc.typeArticle

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu